A Multicentric, Retrospective Efficacy and Safety Study of Nanosomal Docetaxel Lipid Suspension in Metastatic Castration-Resistant Prostate Cancer
Table 1
Demographic and baseline characteristics.
Characteristics
2-weekly NDLS (n = 9)
3-weekly NDLS (n = 15)
Age (years), n (%)
<65 years
2 (22.22)
7 (46.67)
65–74 years
3 (33.33)
4 (26.67)
≥75 years
4 (44.44)
4 (26.67)
Baseline BSA (median (range))
1.7 (1.5–1.9)
1.7 (1.2–1.9)
Median follow-up duration, months (range)
14.7 (5.5–25.7)
12.2 (7.9–15.6)
ECOG performance score, n
0
5 (55.55)
3 (20)
1
3 (33.33)
8 (53.33)
2
1 (11.11)
2 (13.33)
3
0
2 (13.33)
Gleason score at initial diagnosis
≤7
4 (44.44)
13 (86.67)
8
1 (11.11)
2 (13.33)
≥9
2 (22.22)
0
Unknown
2 (22.22)
0
Median PSA at baseline, (range), ng/mL
226 (18.17–510)
28 (1.6–2030)
Median baseline Hb (range)
10.9 (9.8–12.7)
10.8 (8.2–13.1)
Metastasis site
Bone
7 (77.77)
15 (100)
Unknown
2 (22.22)
0
Previous therapy
Radiotherapy
3 (33.33)
4 (26.67)
Prostatectomy
5 (55.55)
12 (80)
Orchiectomy
4 (44.4)
11 (73.3)
Previous systemic therapy
Bicalutamide
0
4 (26.67)
Abiraterone
0
8 (53.33)
Comorbidities
Diabetes
2 (22.22)
6 (40)
Hypertension
0
7 (46.67)
BSA = body surface area, ECOG = Eastern Cooperative Oncology Group, Hb = hemoglobin; NDLS = nanosomal docetaxel lipid suspension, PSA = prostate specific antigen. Baseline BSA was not available for one patient who received 2-weekly NDLS. Other comorbidities include tuberculosis, heart disease, asthma, and abdominal hernia.
